Abstract 662P
Background
IMM2520 consists of a PD-L1 antibody with an engineered ADCC-enhanced IgG1 Fc region, linked to the domain of SIRPα at the N-terminus of heavy chains. Blockade of PD-L1 and CD47- SIRPα pathway fully activate macrophages and induce enhanced ADCP and ADCC activity, leading to potent integrated antitumor response.
Methods
This is an open-label, first in human, dose escalation and dose expansion phase1 study to evaluate the safety, RP2D/MTD and anti-tumor effect for IMM2520 in pts with advanced solid tumor. The dose escalation was designed with an accelerated titration at first dose level followed by standard 3+3 design. IMM2520 was administered weekly in a 28 day-cycle. Additional patients will be enrolled for potential RP2D to identify optimized dose level. Here we report results in ongoing dose escalation stage.
Results
As of 4 Apr 2024, 18 patients (pts) were treated at 5 dose levels (from 0.1mpk to 4mpk). Most pts (61%) previously received ≥ 3 lines of systemic anti-tumor therapy, including 9 (50%) pts with PD-(L)1 therapy history. No DLTs were observed yet. All pts reported treatment-related adverse event (TRAE), of which 10 (56%) pts were ≥ Grade 3. The most common TRAE of any grade was platelet decreased (89%), anemia (67%), white blood cell decreased (56%) and infusion-related reaction (IRR) (56%). The most common TRAE of ≥ Grade 3 was lymphocyte decreased (50%), platelet decreased (33%) and anorexia (5.6%). No AE leading to treatment discontinuation was observed. Of 11 efficacy evaluable pts,1 unconfirmed partial response (PR) in small cell lung cancer (SCLC) at 2mpk (with 2 previous lines of therapy including immunotherapy and negative PD-L1 expression) and 5 stable disease (SD) were observed, including 1 cervical cancer with 21.1% tumor shrinkage and 1 colorectal cancer with 11.1% tumor shrinkage. Pharmacodynamic biomarker included CD47 Target occupancy (TO) on peripheral circulating CD3+T cells using flow cytometry analysis. The rate of CD47 TO was mild and exhibits a dose-dependent trend.
Conclusions
IMM2520 showed tolerance at the evaluated doses and preliminary anti-tumor activity in advanced solid tumor, especially for SCLC. The dose escalation is ongoing.
Clinical trial identification
NCT05780307.
Editorial acknowledgement
Legal entity responsible for the study
ImmuneOnco BioPharmaceuticals (Shanghai) Inc.
Funding
ImmuneOnco BioPharmaceuticals (Shanghai) Inc.
Disclosure
A. Wu, X. Zhao, Z. Wang, Q. Lu: Financial Interests, Personal, Full or part-time Employment: ImmuneOnco BioPharmaceuticals (Shanghai) Inc. W. Tian: Financial Interests, Personal, Stocks or ownership: ImmuneOnco BioPharmaceuticals (Shanghai) Inc. All other authors have declared no conflicts of interest.
Resources from the same session
723P - A phase II study of cadonilimab plus chemotherapy in persistent recurrent/ metastatic cervical cancer patients who failed previous immuno/chemotherapy
Presenter: Li Xiaoling Li
Session: Poster session 01
724P - Preliminary outcomes from a phase Ib/II study of the highly potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced cervical cancer
Presenter: Guiling Li
Session: Poster session 01
725P - Treatment of patients with metastatic or relapsed cervical cancer: Results from a quality assurance program of the AGO Study Group
Presenter: Dominik Denschlag
Session: Poster session 01
726P - Efficacy and safety of pembrolizumab plus olaparib combination therapy in recurrent cervical cancer progressed on platinum-based chemotherapy: Results from the phase II trial of GOTIC-025
Presenter: Kosei Hasegawa
Session: Poster session 01
727P - Real-world efficacy and safety of cadonilimab in recurrent or metastatic cervical cancer: A multicenter retrospective analysis in China
Presenter: Yang Sun
Session: Poster session 01
Resources:
Abstract
728P - Chemotherapy plus tislelizumab in young patients with cervical cancer preserve fertility: A phase II study
Presenter: Danbo Wang
Session: Poster session 01
729P - Patterns of survivorship care of cervical cancer patients with or without HIV infection in Botswana 2015-2022
Presenter: Sheldon Amoo-Mitchual
Session: Poster session 01
730P - Validation of circulating tumor DNA for prognostication and monitoring in metastatic endometrial carcinoma: Ancillary results from the phase II randomized GINECO trial UTOLA
Presenter: Guillaume Beinse
Session: Poster session 01
731P - Post-progression survival outcomes in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial who received follow-up immunotherapy
Presenter: Mansoor Raza Mirza
Session: Poster session 01
732P - Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E
Presenter: Stephanie Blank
Session: Poster session 01